Explore Business Standard
A well-known private healthcare group, Fortis on Friday inaugurated a state-of-the-art facility for the specialised treatment of blood cancers and disorders, which it said "represented a critical step" in addressing the urgent need for comprehensive holistic care. The Fortis Institute of Blood Disorders also integrates paediatric and geriatric care, advanced transplant procedures, and hematopathology expertise, all under one roof, Fortis Healthcare said in a release. The Institute also launched CAR-T cell therapy to its extensive network of Bone Marrow Transplant centres in Mohali, Delhi, Gurgaon, Noida, Mumbai and Bangalore, the statement said. This initiative is supported by a commercial collaboration with ImmunoACT, an IIT-Bombay spin-off and pioneer in India's first fully indigenous and commercially approved gene-modified cell therapy. The NexCAR19, India's first market-authorised CAR-T cell therapy, offers a new ray of hope for treating B-cell lymphomas and B-acute lymphoblast